Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients

Tsai, Hung-Chin; Tsai, Yi‐Chun; Hung, Wei‐Wen; Hung, Wei‐Chun; Chang, Chen-Chia; Yu, Ming‐Lung

doi:10.3390/jpm11030238

Cited by 18 publications

(17 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 Other analyses of microbiotal content in patients with moderate to severe NAFLD have identified correlation with Firmicutes content. 69 In addition to its impact on metabolic diseases of the liver, the microbiome has been implicated in the development of cirrhosis and hepatocellular carcinoma. Disruptions in the gut microbiota have been associated with a cycle of hepatocyte injury and regeneration, in a pattern often seen with other chronic liver diseases on a pathway toward cirrhosis.…”

Section: Impact Of the Gut Microbiome On Metabolic Disorders And Live...mentioning

confidence: 99%

Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders

Zhao

Tait

Minacapelli

et al. 2022

Gastro Hep Advances

View full text Add to dashboard Cite

The circadian clock and gut microbiome play integral roles in preserving metabolic homeostasis. Circadian rhythms represent an endogenous time-keeping system that regulates cell and organ functions and synchronizes physiology with external cues to establish metabolic homeostasis. A variety of functions throughout the gastrointestinal tract and liver are under circadian control, including nutrient transport, processing, and detoxification. The gut microbiota also plays an essential role in host metabolism, regulating processes such as digestion, inflammatory modulation, and bile acid metabolism. Both the circadian clock and the gut microbiota influence each other in a reciprocal fashion, as gut dysbiosis can precipitate circadian asynchrony, and vice-versa. Disruption of either system impacts homeostasis in a bidirectional manner and can contribute to metabolic dysfunction. Evidence suggests such disruptions can lead to the development of metabolic diseases, including obesity, diabetes, nonalcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma. This review will provide a basic overview of the circadian and gut microbial systems, how they are intertwined, and their impact on the liver and gastrointestinal tract and in the development of metabolic disease. Particular areas of discussion include epigenetic regulation of circadian pathways as well as a mechanistic overview of microbial dysbiosis. In addition, therapeutic targets of these systems, including dietary modifications, behavioral modifications, and microbial-directed therapies, will be explored.

show abstract

Section: Impact Of the Gut Microbiome On Metabolic Disorders And Live...mentioning

confidence: 99%

Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders

Zhao

Tait

Minacapelli

et al. 2022

Gastro Hep Advances

View full text Add to dashboard Cite

show abstract

“…We invited patients with T2D who attended the outpatient clinics of a tertiary hospital in Southern Taiwan from October 2016 to August 2017 to participate in this observational study. A diagnosis of T2D was based on a previous history of T2D, blood glucose values defined by the American Diabetes Association, or the use of antidiabetic drugs, as in our previous study [ 26 ]. All of the patients were enrolled in an education program on diabetes at our hospital, and they followed the guidelines for a diabetic diet.…”

Section: Methodsmentioning

confidence: 99%

“…Bacterial 16S rRNA genes in the fecal samples were quantified using real-time qPCR on a StepOnePlus Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA), as previously reported [ 26 , 30 , 31 , 32 ]. Supplementary Table S1 lists the eight pairs of 16S rRNA gene primers specific to the C. leptum group: E. coli , Bacteroidetes , Firmicutes , Bacteroides , F. prausnitzii, Bifidobacterium , and A. muciniphila that were used in this study.…”

Section: Methodsmentioning

confidence: 99%

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus

Tsai

Hung

et al. 2021

Nutrients

Self Cite

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular disease (CVD). The gut microbiota may contribute to the onset and progression of T2D and CVD. The aim of this study was to evaluate the relationship between the gut microbiota and subclinical CVD in T2D patients. This cross-sectional study used echocardiographic data to evaluate the cardiac structure and function in T2D patients. We used a quantitative polymerase chain reaction to measure the abundances of targeted fecal bacterial species that have been associated with T2D, including Bacteroidetes, Firmicutes, Clostridium leptum group, Faecalibacterium prausnitzii, Bacteroides, Bifidobacterium, Akkermansia muciniphila, and Escherichia coli. A total of 155 subjects were enrolled (mean age 62.9 ± 10.1 years; 57.4% male and 42.6% female). Phyla Bacteroidetes and Firmicutes and genera Bacteroides were positively correlated with the left ventricular ejection fraction. Low levels of phylum Firmicutes were associated with an increased risk of left ventricular hypertrophy. High levels of both phylum Bacteroidetes and genera Bacteroides were negatively associated with diastolic dysfunction. A high phylum Firmicutes/Bacteroidetes (F/B) ratio and low level of genera Bacteroides were correlated with an increased left atrial diameter. Phyla Firmicutes and Bacteroidetes, the F/B ratio, and the genera Bacteroides were associated with variations in the cardiac structure and systolic and diastolic dysfunction in T2D patients. These findings suggest that changes in the gut microbiome may be the potential marker of the development of subclinical CVD in T2D patients.

show abstract

“…It is an important health issue worldwide. Gradually, NAFLD is becoming the most common cause of further progression to end-stage liver diseases (1). The increasing prevalence of NAFLD is related to type-2 diabetes mellitus (T2DM).…”

Section: Introductionmentioning

confidence: 99%

Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern Chinese Patients With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus

Han

Huang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection has been reported to affect the bacterial characteristics in the host. We aimed to elucidate the compositional and functional characteristics of the microbiota in southern Chinese patients with coexistent HBV infection, non-alcoholic fatty liver disease (NAFLD), and type-2 diabetes mellitus (T2DM).Methods: Healthy controls (HCs) and patients with coexistent NAFLD and T2DM were enrolled. Patients were divided into two groups: N1 (without HBV infection) and N2 (with HBV infection). Stool samples were collected for 16s RNA gene sequencing and untargeted metabolomics analysis.Results: Bacterial diversity was decreased in the N2 group. There was a significantly lower abundance of bacteria of Faecalibacterium, Gemmiger, and Clostridium_XIVA genera, but a higher abundance of Megamonas and Phascolarctobacterium genera in the N2 group. Compared with the N1 group, the abundance of Gemmiger species was even lower, and alterations in the abundance of Phascolarctobacterium and Clostridium_XIVA genera only occurred in the N2 group. There were significantly different fecal metabolic features, which were enriched in glucose and lipid metabolic pathways (e.g., fatty acid and glycerophospholipid metabolism) between the N2 and HC groups. Metabolites in glycerophospholipid metabolism, such as Sn-3-o-(geranylgeranyl)glycerol1-phosphate, were even higher in the N2 group than in the N1 group. The decreased Faecalibacterium and Gemmiger contributed to the increased level of Sn-3-o-(geranylgeranyl) glycerol1-phosphate, palmitoylcarnitine, and serum triglycerides. Clostridium_XIVA species were positively correlated to 15(s)-hpete. Megamonas species were positively correlated with the serum level of glucose indirectly.Conclusions: The distinct gut-microbiome profile associated with HBV infection has a role in lipid metabolism and glucose metabolism in patients with coexistent NAFLD and T2DM.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03525769.

show abstract

Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients

Cited by 18 publications

References 41 publications

Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders

Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus

Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern Chinese Patients With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus

Contact Info

Product

Resources

About